New drug aims to cut opioid use after heart and Weight-Loss surgery

NCT ID NCT07539623

Recruiting now Symptom relief Sponsor: Icahn School of Medicine at Mount Sinai Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding suzetrigine, a new non-opioid pain drug, to standard pain management can lower the amount of opioids needed after weight-loss or heart surgery. About 235 adults will be randomly assigned to receive either suzetrigine or a placebo alongside usual care. The main goal is to measure total opioid use and pain scores after surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Suzetrigine
What this could lead to: If it works, this could offer a new way to manage post-surgery pain with fewer opioids, potentially reducing addiction risk and side effects.
What could go wrong: This is a phase 3 trial, but results may not apply to all surgeries or patients. The drug may not reduce opioid use enough or could have unknown side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BARIATRIC SURGERY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Pain, Postoperative

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BARIATRIC SURGERY CARDIAC SURGERY WITH STERNOTOMY POST-OPERATIVE PAIN

Contacts and locations

Locations

Mount Sinai Morningside
RECRUITING

New York, New York, 10025, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.